期刊
TROPICAL MEDICINE & INTERNATIONAL HEALTH
卷 6, 期 5, 页码 412-420出版社
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-3156.2001.00725.x
关键词
Angola; drug levels; drug resistance; melarsoprol; pharmacokinetics; sleeping sickness; trypanosomiasis; trypanosomes
Melarsoprol, an organo-arsenical drug, has been the drug of choice for late-stage trypanosomiasis for 50 years. Because of the lack of alternatives any abatement of this medication will have a dramatic negative impact on the perspectives for patients. As a large number of patients refractory to melarsoprol treatment was recently reported from northern Uganda and northern Angola, we investigated in northern Angola whether interpatient pharmacokinetic differences influence the outcome of melarsoprol treatment. Drug levels were determined by a biological assay in serum and cerebrospinal fluid (CSF) of 22 patients. Nine patients could be successfully treated, eight were refractory and the outcome was unclear or no adequate follow-up information was available for five patients. No differences in the pharmacokinetic parameters (maximum serum concentration C-max, half-life t(1/2 beta), total clearance C-L and the Volume of distribution V-ss) could be detected between the groups. Serum and CSF concentrations for all patients were in the expected range. This result indicates that other underlying factors are responsible far treatment failures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据